546 related articles for article (PubMed ID: 33335120)
1. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
[TBL] [Abstract][Full Text] [Related]
2. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models.
Daldin M; Fodale V; Cariulo C; Azzollini L; Verani M; Martufi P; Spiezia MC; Deguire SM; Cherubini M; Macdonald D; Weiss A; Bresciani A; Vonsattel JG; Petricca L; Marsh JL; Gines S; Santimone I; Marano M; Lashuel HA; Squitieri F; Caricasole A
Sci Rep; 2017 Jul; 7(1):5070. PubMed ID: 28698602
[TBL] [Abstract][Full Text] [Related]
4. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
[TBL] [Abstract][Full Text] [Related]
5. Meso scale discovery-based assays for the detection of aggregated huntingtin.
Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
[TBL] [Abstract][Full Text] [Related]
6. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
[TBL] [Abstract][Full Text] [Related]
7. Quantifying Huntingtin Protein in Human Cerebrospinal Fluid Using a Novel Polyglutamine Length-Independent Assay.
Fodale V; Pintauro R; Daldin M; Spiezia MC; Macdonald D; Bresciani A
J Huntingtons Dis; 2022; 11(3):291-305. PubMed ID: 35938256
[TBL] [Abstract][Full Text] [Related]
8. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
[TBL] [Abstract][Full Text] [Related]
10. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
Fodale V; Boggio R; Daldin M; Cariulo C; Spiezia MC; Byrne LM; Leavitt BR; Wild EJ; Macdonald D; Weiss A; Bresciani A
J Huntingtons Dis; 2017; 6(4):349-361. PubMed ID: 29125493
[TBL] [Abstract][Full Text] [Related]
11. Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.
Song H; Li H; Guo S; Pan Y; Fu Y; Zhou Z; Li Z; Wen X; Sun X; He B; Gu H; Zhao Q; Wang C; An P; Luo S; Hu Y; Xie X; Lu B
Brain; 2018 Jun; 141(6):1782-1798. PubMed ID: 29608652
[TBL] [Abstract][Full Text] [Related]
12. Copper enhances aggregational toxicity of mutant huntingtin in a Drosophila model of Huntington's Disease.
Lobato AG; Ortiz-Vega N; Zhu Y; Neupane D; Meier KK; Zhai RG
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166928. PubMed ID: 38660915
[TBL] [Abstract][Full Text] [Related]
13. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
15. A toxic mutant huntingtin species is resistant to selective autophagy.
Fu Y; Wu P; Pan Y; Sun X; Yang H; Difiglia M; Lu B
Nat Chem Biol; 2017 Nov; 13(11):1152-1154. PubMed ID: 28869595
[TBL] [Abstract][Full Text] [Related]
16. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
[TBL] [Abstract][Full Text] [Related]
17. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
18. HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice.
Chen L; Qin Y; Guo T; Zhu W; Lin J; Xing T; Duan X; Zhang Y; Ruan E; Li X; Yin P; Li S; Li XJ; Yang S
Cell Death Dis; 2024 May; 15(5):337. PubMed ID: 38744826
[TBL] [Abstract][Full Text] [Related]
19. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
[TBL] [Abstract][Full Text] [Related]
20. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
